应当要提供代表性资料以支持有机杂质的评估。一般来说,是不需要残留溶剂的代表性资料的。仪器输出和原始数值(比如,峰面积)及合适的标记和标注(比如,色谱峰的保留时间,核磁共振的化学位移和耦合常数)都应当要提供。根据所提供的定量限和仪器输出对杂质情况进行评估。还应当要提供其它资料以确认杂质情况得到了充分地界定。比如说,比如说,代表性图谱选用的检测波长是205nm,则可以将拟定的运行时间延长至两倍以支持分析方法的专属性。
For quantitation purposes, the response factor of the drug substance may be
used for impurities without a reference standard. In cases where the response factors are not close, this practice may still be acceptable, provided a correction factor is applied or the impurities are, in fact, being overestimated. Acceptance criteria and analytical procedures used to estimate identified or unidentified impurities often are based on analytical assumptions (e.g., equivalent detector response). Assumptions should be discussed and justified.
在定量分析时,原料药的响应因子可用于没有相应对照品的杂质。如果响应因子不接近的话,只要应用了较正因子或或者杂质实际上是被高估的话,这样做也是可行的。用于评估指定杂质或未指定杂质的合格标准和分析方法经常都是基于分析假设的(比如,相当的检测器响应)。应当要对这些假设进行讨论和合理性说明。
ii. Drug Substance
Data should be submitted showing the separation and detection of impurities using spiked or stress samples. Complete impurity profiles as graphic output (e.g., chromatograms) and raw data (e.g, integrated peak areas) of representative batches should be submitted in the sections on analytical procedures and controls for the drug substance. For ANDAs and related submissions, appropriate information for the batches used in the biobatch or submission batch should be provided. All responses (e.g., peaks) should be labeled. The analytical procedure used should be capable of differentiating changes, if any, between past and present batches. The quantitation limit and the type of organic impurity (e.g., degradant, process impurity) should be stated. The analytical procedure number, batch number, manufacturing date and site, and date of analysis should be provided.
ii.原料药
ANDA和相关的递交,用于生物利用度研究的批次(biobatch)或者提交批次(submission batch)的相关资料应当要提供。所有的响应(比如,色谱峰)都应当要进行标注。所用的分析方法应当要有能力区分先前批次和当前批次之间的变化,如果有这些变化的话。应当要说明定量限和有机杂质的类型(比如:降解物,工艺杂质)。还需提供分析方法编号,批号,生产日期和生产地点及分析日期。
iii. Drug Product
Information such as instrument output (e.g., chromatograms) and raw data (e.g., integrated peak areas) from representative batches under long-term and accelerated stability conditions, and stressed samples should be submitted in the sections on analytical procedures and controls of the drug product. For ANDAs and related submissions, appropriate information for the biobatch or submission batch should be provided. References to the raw data (e.g., chromatograms) should be included in the stability section of the application.
iii.制剂
在制剂的分析方法和控制一章中,应要当提供的资料有:代表性批号在长期和加速稳定性实验条件下及强降解实验条件下的仪器输出(如,图谱)和原始资料(如峰面积)。对于ANDA和相关递交,应当要提供生物利用度实验批次或递交批次的适当资料。在申请的稳定性章节中应当要引用原始资料(比如:图谱)。 At a minimum, the submission should include instrument output and raw data for release testing and at the latest available time point for the same batch. All responses (e.g., peaks) should
美国FDA分析方法验证指南中英文对照美国FDA分析方法验证指南中英文对照隐藏>> 美国FDA 分析方法验证指南中英文对照(四) 美国 FDA 分析方法验证指南中英文对照 (http...
美国FDA分析方法验证指南中英文对照美国FDA分析方法验证指南中英文对照隐藏>> 聿莃 蚂肂罗莂蛳袅 芄莁蒄肀膀 莀薆袃肆荿 蚈聿羂葿螁袂 芀蒈蒀蚄嗉 蒇薃袀...
美国FDA分析方法验证指南中英文对照_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档 美国FDA分析方法验证指南中英文对照_医药卫生_专业资料。分析方法验证指南...
翻译:胡剀 整理:chenpq (中英对照)美国 FDA 分析方法验证指南(6/50) 审评化学家会对 NDA 或 ANDA 中的分析方法和验证资料进行评审。 On request from FDA, ...
(中英对照)美国FDA分析方法验证指南_电力/水利_工程科技_专业资料 暂无评价0人阅读0次下载举报文档 (中英对照)美国FDA分析方法验证指南_电力/水利_工程科技_...
美国fda分析方法验证指南中... 37页 1财富值 (中英对照)_美国FDA分析方.....32 2 I. 绪论 本指南旨在为申请者提供建议,以帮助其提交分析方法,方法验证...
美国fda分析方法验证指南中... 37页 1财富值 (中英对照)_美国FDA分析方.....31 I.目的 本指南概述了人用和兽用药品和医疗器械的生产过程(工艺)验证的总则...
FDA清洁工艺验证指南中英... 12页 1下载券 美国FDA分析方法验证指南... 20...Preparing for FDA Preapproval Inspections 准备FDA认证前检查 Richard Needham, ...
清洁验证检查FDA指南(中英文对照)_医药卫生_专业资料。很好的验证The AlliancePharm(US ), Inc. www.alliancepharm.us 洲际联盟(北京)资讯有限公司 《美国FDA认证...
热门文档